Diatech changes name to Diatide

Article

Peptide radiopharmaceutical developer Diatech has changed itsname to Diatide in a move designed to link itself more closelyto the technology it is developing. The Londonderry, NH-basedcompany announced the change this month after approval by itsboard of

Peptide radiopharmaceutical developer Diatech has changed itsname to Diatide in a move designed to link itself more closelyto the technology it is developing. The Londonderry, NH-basedcompany announced the change this month after approval by itsboard of directors.

Diatide is developing peptide-based imaging and therapy agentsthat are labeled with technetium-99m (SCAN 8/30/95). The firmplans to file a new drug application in 1997 for its lead product,an agent for the detection of deep vein thrombosis.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.